Prof. Yingrui Shi 师颖瑞
Chief Physician, Professor
Department of Radiation Oncology, Hunan Cancer Hospital, Changsha
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation therapy for nasopharyngeal cancer, lung cancer, and esophageal cancer. Focuses on precision radiotherapy for head, neck, and chest tumors.
Dr. Shi is a Chief Physician and Professor with 16 years of experience in tumor radiation therapy. Holds a PhD and serves as Deputy Director of Thoracic Radiation Therapy Department I at Hunan Cancer Hospital. Pioneered radioactive particle implantation in Central China (2003) and image-guided adaptive hypofractionated radiotherapy (2015). Published over 20 core journal papers and two SCI articles.
Professional roles
- Member, Chinese Medical Association Radioactive Particle Implantation Society
- Member, Hunan Anti-Cancer Association Radiation Therapy Professional Committee
- Member, Hunan Anti-Cancer Association Esophageal Cancer Professional Committee
Name order: in Chinese the family name comes first (Shi Yingrui). Papers usually list the name as Yingrui Shi or Shi Y.
Selected publications
29 papers on PubMed matched by name and affiliation; 9 as first or senior author since 2016. Most recent first- or senior-author papers:
- Phytother Res, 2025 (senior author): Quercetin Alleviates Breast Cancer-Related Depression by Inhibiting Neutrophil Extracellular Traps via Inhibition of Sphingosine 1-Phosphate/Sphingosine 1-Phosphate Receptor Axis. PubMed 40313180
- Phytomedicine, 2024 (senior author): Quercetin inhibits neuronal Ferroptosis and promotes immune response by targeting lipid metabolism-related gene PTGS2 to alleviate breast cancer-related depression. PubMed 38815404
- Front Biosci (Landmark Ed), 2023 (senior author): Kaempferol Improves Breast Cancer-Related Depression through the COX-2/PGE2 Pathway. PubMed 38062826
- Int Immunopharmacol, 2023 (senior author): Recent advances in immune checkpoint inhibitor-induced type 1 diabetes mellitus. PubMed 37390646
- Psychopharmacology (Berl), 2023 (senior author): Curcumin protects against doxorubicin induced oxidative stress by regulating the Keap1-Nrf2-ARE and autophagy signaling pathways. PubMed 36949340
- BMC Pulm Med, 2022 (senior author): Risk analysis of grade ≥ 2 radiation pneumonitis based on radiotherapy timeline in stage III/IV non-small cell lung cancer treated with volumetric modulated arc therapy: a retrospective study. PubMed 36344945
- Asia Pac J Clin Oncol, 2021 (senior author): Failure patterns and prognostic factors for cervical node-negative nasopharyngeal carcinoma in the intensity-modulated radiotherapy era. PubMed 33079493
- Ann Transl Med, 2020 (first author): Development of a prognostic signature for bladder cancer based on immune-related genes. PubMed 33313125
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion